Copyright © 2002 by the European Society of Cardiology.
Editorials
Do statins confer early benefit after acute coronary syndromes? The results from FLORIDA
a Division of Cardiology, Department of Medicine, University of California, San Francisco, California, U.S.A.
b Division of Cardiology, San Francisco General Hospital, San Francisco, California, U.S.A.
References
- Liem AH, van Boven AJ, Veeger NJGM. Effect of fluvastatin on ischemia following acute myocardial infarction: a randomized trial. Eur Heart J. 2002;23:19311937
[Abstract/Free Full Text] - Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ. 1995;311:485
[Free Full Text] - Browner WS, Newman TB. Are all significant P values created equal? The analogy between diagnostic tests and clinical research. JAMA. 1987;257:24592463[Abstract]
- Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285:430436
[Abstract/Free Full Text] - Aronow HD, Topol EJ, Roe MT. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001;357:10631068[CrossRef][ISI][Medline]
- Newby LK, Kristinsson A, Bhapkar MV. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA. 2002;287:30873095
[Abstract/Free Full Text] - Schwartz GG, Olsson AG, Ezekowitz MD. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. the MIRACL study: a randomized controlled trial. JAMA. 2001;285:17111718
[Abstract/Free Full Text] - Blazing MA, Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E. The A-to-Z trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive statin therapy. Am Heart J. 2001;142:211217[CrossRef][ISI][Medline]
- Fisher LD. Comments on Bayesians and frequentist analysis and interpretation of clinical trials. Cont Clin Trials. 1996;17:423434[CrossRef]
- Fonarow GC, Gawlinski A, Moughrabi S. Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program: CHAMP. Am J Cardiol. 2001;87:257261[CrossRef][ISI][Medline]
- Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease. The time is now. Circulation. 2001;103:27682770
[Free Full Text]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||